Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
GC Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩159 K
2024-10-29
Market Capitalization
₩1.8 T
2024-10-29
Revenue
₩2 T
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3T | 1.4T | 1.5T | 1.5T | 1.7T | 1.6T | 1.7T | 2.0T |
| Cost of goods sold | 989.0B | 997.4B | 1.1T | 1.0T | 1.1T | 1.1T | 1.2T | 1.4T |
| Gross profit | 354.8B | 383.8B | 512.7B | 544.9B | 641.1B | 499.2B | 501.7B | 609.8B |
| Gross profit margin, % | 28.0% | 34.1% | 35.4% | 37.5% | 30.7% | 29.9% | 30.6% | |
| Operating expense total | 295.7B | 332.1B | 390.4B | 446.9B | 500.5B | 450.2B | 449.8B | 485.0B |
| EBITDA | 52.1B | 48.9B | 116.7B | 179.5B | 122.5B | 10.5B | 24.4B | 139.4B |
| EBITDA margin, % | 3.6% | 7.8% | 11.7% | 7.2% | 0.6% | 1.5% | 7.0% | |
| EBIT | 33.3B | 11.8B | 90.0B | 171.6B | 97.8B | (5.9B) | (17.1B) | 17.5B |
| EBIT margin, % | 0.9% | 6.0% | 11.2% | 5.7% | -0.4% | -1.0% | 0.9% | |
| Interest income | 28.4B | 8.7B | 40.7B | 21.1B | 15.4B | 10.9B | 25.9B | 21.7B |
| Interest expense | 11.6B | 26.7B | 26.2B | 20.2B | 27.5B | 32.1B | 49.9B | 74.5B |
| Pre tax profit | 50.2B | (6.1B) | 104.5B | 172.6B | 85.7B | (27.1B) | (41.1B) | (35.3B) |
| Income tax expense | 15.9B | 5.1B | 15.4B | 35.6B | 16.3B | (7.3B) | 1.5B | (5.6B) |
| Net Income | 34.2B | (11.3B) | 89.1B | 136.9B | 69.4B | (19.8B) | (42.6B) | (29.7B) |